Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 1.00 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.73 |
| ▸ | PNP | P00491 | 10/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | EDNRA | P25101 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | HBB | P68871 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8175624 | 0.99 | TK1 (0.97) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL3836263 | 0.96 | TK1 (0.92) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL350397 | 0.90 | TK1 (0.82) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL8196749 | 0.88 | TK1 (0.78) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL29286376 | 0.87 | TK1 (0.76) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL8522271 | 0.86 | TK1 (0.76) | TK1HPRT1PNP | |
| SCHEMBL15743134 | 0.86 | TK1 (0.76) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL3793003 | 0.86 | TK1 (0.76) | TK1HPRT1PNP | |
| SCHEMBL6061489 | 0.86 | TK1 (0.75) | TK1HPRT1PNPUSP2TSHR | |
| SCHEMBL6272299 | 0.85 | TK1 (0.74) | TK1HPRT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594987-B1 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | GENEFORM TECHNOLOGIES LTD (GB) | 2009-05-27 | — | — | EP | claimed |
| EP-1594987-A2 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | Hoser, Mark J. (GB) | 2005-11-16 | — | — | EP | claimed |
| WO-2004074503-A2 | NUCLEIC ACID SEQUENCING METHODS, KITS AND REAGENTS | HOSER MARK J (GB) | 2004-09-02 | — | — | WO | claimed |
| US-20020169140-A1 | Combination therapy for reduction of toxicity of chemotherapeutic agents | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | claimed |
| WO-2002069949-A2 | COMBINATION THERAPY FOR REDUCTION OF TOXYCITY OF CHEMOTHERAPEUTIC AGENTS | PRENDERGAST PATRICK T (IE) | 2002-09-12 | — | — | WO | claimed |
| US-5446045-A | Viricides for treating AIDS, viral diseases | TRIPLEX PHARMACEUTICAL CORPORATION | 1995-08-29 | — | — | US | claimed |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250223639-A1 | PROCESS FOR COGNATE NUCLEOTIDE DETECTION IN A NUCLEIC ACID SEQUENCING WORKFLOW | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-12344890-B2 | Process for cognate nucleotide detection in a nucleic acid sequencing workflow | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4556010-A2 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | Emory University (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3750544-B1 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | UNIV EMORY (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2024-12-19 | — | — | US | disclosed |
| CN-107898790-B | Antiviral JAK inhibitors for the treatment or prevention of retroviral and other viral infections | 埃默里大学 | 2024-06-21 | — | — | CN | disclosed |
| EP-0112353-A1 | NOVEL DERIVATIVES OF GUANINE I | Astra Läkemedel Aktiebolag (SE) | 1984-07-04 | — | — | EP | disclosed |
| EP-0103552-A2 | Novel derivatives of guanine | Astra Läkemedel Aktiebolag (SE) | 1984-03-21 | — | — | EP | disclosed |
| EP-0103551-A2 | Novel derivatives of guanine | Astra Läkemedel Aktiebolag (SE) | 1984-03-21 | — | — | EP | disclosed |
| WO-1984000168-A1 | NOVEL DERIVATIVES OF GUANINE II | ASTRA LAEKEMEDEL AB (SE) | 1984-01-19 | — | — | WO | disclosed |
| WO-1984000167-A1 | NOVEL DERIVATIVES OF GUANINE I | ASTRA LAEKEMEDEL AB (SE) | 1984-01-19 | — | — | WO | disclosed |
| WO-1982002202-A1 | NOVEL DERIVATIVES OF GUANINE | ASTRA LAEKEMEDEL AB (SE) | 1982-07-08 | — | — | WO | disclosed |
| EP-0055239-A1 | Novel derivatives of guanine | Astra Läkemedel Aktiebolag (SE) | 1982-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223639-A1 | PROCESS FOR COGNATE NUCLEOTIDE DETECTION IN A NUCLEIC ACID SEQUENCING WORKFLOW | RNGTT, POLRMT, POLM | TK1 104/4885HPRT1 127/4885PNP 28/4885 |
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | TK1 5/4885HPRT1 14/4885PNP 2/4885 |
| US-12344890-B2 | Process for cognate nucleotide detection in a nucleic acid sequencing workflow | RNGTT, POLRMT, POLM | TK1 104/4885HPRT1 127/4885PNP 28/4885 |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | TK1 24/4885HPRT1 17/4885PNP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.